Organ-transplant recipients often reject donated organs, but a new, two-pronged strategy developed by UCSF researchers to specifically weaken immune responses that target transplanted tissue has shown promise.
February 06, 2014
Scientists, harnessing the power of regenerative medicine, have developed a technique in animal models that could replenish the cells destroyed by type 1 diabetes.
January 31, 2014
Four UCSF-affiliated researchers are among 102 recipients of the Presidential Early Career Awards for Scientists and Engineers.
January 14, 2014
Two new studies led by UC San Francisco scientists shed new light on the nature of beta cells, the insulin-producing cells in the pancreas that are compromised in diabetes.
December 16, 2013
Taxing sugar-sweetened beverages is likely to decrease consumption, resulting in lower rates of diabetes and heart disease, and these health benefits are expected to be greatest for the low-income, Hispanic and African-American Californians who are at highest risk of diabetes, according to a new analysis led by researchers at UC San Francisco.
November 14, 2013
For the worst cases of type 1 diabetes, islet transplantation has freed hundreds of people from complete insulin dependence. UCSF is leading a push to bring this experimental procedure into the mainstream.
November 05, 2013
The United States faces a severe shortage of primary health care providers. In a series of papers published in Health Affairs, UCSF researchers advocated a number of potential solutions to the problem.
September 13, 2013
The Madison Clinic for Pediatric Diabetes at UCSF Benioff Children’s Hospital works with young type 1 diabetes patients to prepare them to manage their own care as they transition to adulthood.
September 09, 2013
Scientists from UCSF have identified a new way to manipulate the immune system that may keep it from attacking the body’s own molecules in autoimmune diseases such as type 1 diabetes, rheumatoid arthritis and multiple sclerosis.
August 07, 2013
An experimental drug designed to block the advance of type 1 diabetes in its earliest stages has proven strikingly effective over two years in about half of the patients who participated in the phase 2 clinical trial, UCSF and Yale University report.